- Home
- VYGR vs NRO Comparison
VYGR vs NRO Comparison
Compare VYGR & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- NRO
- Stock Information
- Founded
- VYGR 2013
- NRO 2003
- Country
- VYGR United States
- NRO United States
- Employees
- VYGR N/A
- NRO N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- NRO Finance/Investors Services
- Sector
- VYGR Health Care
- NRO Finance
- Exchange
- VYGR Nasdaq
- NRO Nasdaq
- Market Cap
- VYGR 231.9M
- NRO 199.6M
- IPO Year
- VYGR 2015
- NRO N/A
- Fundamental
- Price
- VYGR $4.23
- NRO $3.17
- Analyst Decision
- VYGR Strong Buy
- NRO
- Analyst Count
- VYGR 7
- NRO 0
- Target Price
- VYGR $17.00
- NRO N/A
- AVG Volume (30 Days)
- VYGR 551.0K
- NRO 239.4K
- Earning Date
- VYGR 11-06-2025
- NRO 01-01-0001
- Dividend Yield
- VYGR N/A
- NRO 11.41%
- EPS Growth
- VYGR N/A
- NRO N/A
- EPS
- VYGR N/A
- NRO N/A
- Revenue
- VYGR $42,580,000.00
- NRO N/A
- Revenue This Year
- VYGR N/A
- NRO N/A
- Revenue Next Year
- VYGR $107.10
- NRO N/A
- P/E Ratio
- VYGR N/A
- NRO N/A
- Revenue Growth
- VYGR N/A
- NRO N/A
- 52 Week Low
- VYGR $2.65
- NRO $2.51
- 52 Week High
- VYGR $7.44
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- VYGR 41.58
- NRO 45.96
- Support Level
- VYGR $4.10
- NRO $3.13
- Resistance Level
- VYGR $4.30
- NRO $3.21
- Average True Range (ATR)
- VYGR 0.26
- NRO 0.04
- MACD
- VYGR -0.10
- NRO 0.00
- Stochastic Oscillator
- VYGR 20.89
- NRO 35.00
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").